{
    "id": 11636,
    "fullName": "EGFR C797S",
    "impact": "missense",
    "proteinEffect": "unknown",
    "geneVariantDescriptions": [
        {
            "description": "EGFR C797S lies within the ATP-binding pocket in the protein kinase domain of the Egfr protein (PMID: 25964297). C797S has been demonstrated to confer resistance to third-generation Egfr inhibitors (PMID: 25964297, PMID: 25948633, PMID: 29410323), is enriched in growth factor-independent cells in a high-throughput screening assay, but does not support growth factor-independent proliferation in culture, and results in Egfr phosphorylation upon Egf stimulation to similar levels as wild-type protein in culture (PMID: 30952700), and therefore, its effect on Egfr protein function is unknown.",
            "references": [
                {
                    "id": 3620,
                    "pubMedId": 25964297,
                    "title": "The Allelic Context of the C797S Mutation Acquired upon Treatment with Third-Generation EGFR Inhibitors Impacts Sensitivity to Subsequent Treatment Strategies.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25964297"
                },
                {
                    "id": 11558,
                    "pubMedId": 29410323,
                    "title": "EGFR T790M and C797S Mutations as Mechanisms of Acquired Resistance to Dacomitinib.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29410323"
                },
                {
                    "id": 15530,
                    "pubMedId": 30952700,
                    "title": "An unbiased in vitro screen for activating epidermal growth factor receptor mutations.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30952700"
                },
                {
                    "id": 3618,
                    "pubMedId": 25948633,
                    "title": "EGFR Mutations and Resistance to Irreversible Pyrimidine-Based EGFR Inhibitors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25948633"
                }
            ]
        }
    ],
    "type": null,
    "gene": {
        "id": 1956,
        "geneSymbol": "EGFR",
        "terms": [
            "EGFR",
            "ERBB",
            "ERBB1",
            "HER1",
            "mENA",
            "NISBD2",
            "PIG61"
        ]
    },
    "variant": "C797S",
    "createDate": "09/09/2015",
    "updateDate": "02/10/2020",
    "referenceTranscriptCoordinates": {
        "id": 135545,
        "transcript": "NM_005228",
        "gDna": "chr7:g.55181398T>A",
        "cDna": "c.2389T>A",
        "protein": "p.C797S",
        "sourceDb": "RefSeq",
        "refGenomeBuild": "GRCh38/hg38"
    },
    "partnerGenes": [
        
    ],
    "evidence": [
        {
            "id": 16354,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, transformed cells expressing EGFR C797S were sensitive to treatment with Erbitux (cetuximab) in culture (PMID: 29141884).",
            "molecularProfile": {
                "id": 11686,
                "profileName": "EGFR C797S"
            },
            "therapy": {
                "id": 694,
                "therapyName": "Cetuximab",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 10358,
                    "pubMedId": 29141884,
                    "title": "A method of high-throughput functional evaluation of EGFR gene variants of unknown significance in cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29141884"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 16350,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, transformed cells expressing EGFR C797S were resistant to treatment with Gilotrif (afatinib) in culture (PMID: 29141884).",
            "molecularProfile": {
                "id": 11686,
                "profileName": "EGFR C797S"
            },
            "therapy": {
                "id": 623,
                "therapyName": "Afatinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 10358,
                    "pubMedId": 29141884,
                    "title": "A method of high-throughput functional evaluation of EGFR gene variants of unknown significance in cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29141884"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 16351,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, transformed cells expressing EGFR C797S were resistant to treatment with Tagrisso (osimertinib) in culture (PMID: 29141884).",
            "molecularProfile": {
                "id": 11686,
                "profileName": "EGFR C797S"
            },
            "therapy": {
                "id": 660,
                "therapyName": "Osimertinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 10358,
                    "pubMedId": 29141884,
                    "title": "A method of high-throughput functional evaluation of EGFR gene variants of unknown significance in cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29141884"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 16353,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, transformed cells expressing EGFR C797S were resistant to treatment with Rociletinib (CO-1686) in culture (PMID: 29141884).",
            "molecularProfile": {
                "id": 11686,
                "profileName": "EGFR C797S"
            },
            "therapy": {
                "id": 1003,
                "therapyName": "Rociletinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 10358,
                    "pubMedId": 29141884,
                    "title": "A method of high-throughput functional evaluation of EGFR gene variants of unknown significance in cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29141884"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 18663,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, JBJ-04-125-02 did not inhibit proliferation of a transformed mouse cell line expressing EGFR E746_A750del, C797S and T790M in culture (PMID: 31092401).",
            "molecularProfile": {
                "id": 11688,
                "profileName": "EGFR E746_A750del EGFR T790M EGFR C797S"
            },
            "therapy": {
                "id": 8684,
                "therapyName": "JBJ-04-125-02",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 16071,
                    "pubMedId": 31092401,
                    "title": "Single and Dual Targeting of Mutant EGFR with an Allosteric Inhibitor.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31092401"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 10305,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Erbitux (cetuximab) did not inhibit growth of transformed cells expressing a EGFR E746_A750del/T790M/C797S triple mutation in culture (PMID: 25948633).",
            "molecularProfile": {
                "id": 11688,
                "profileName": "EGFR E746_A750del EGFR T790M EGFR C797S"
            },
            "therapy": {
                "id": 694,
                "therapyName": "Cetuximab",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "no benefit",
            "references": [
                {
                    "id": 3618,
                    "pubMedId": 25948633,
                    "title": "EGFR Mutations and Resistance to Irreversible Pyrimidine-Based EGFR Inhibitors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25948633"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 16835,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, TQB3804 inhibited Egfr downstream signaling, resulted in growth inhibition of transformed cells expressing EGFR E746_A750del, T790M, and C797S triple mutations in culture and in cell line xenograft models (Proceedings of the American Association for Cancer Research, Vol 60, Mar 2019, Abstract #1320).",
            "molecularProfile": {
                "id": 11688,
                "profileName": "EGFR E746_A750del EGFR T790M EGFR C797S"
            },
            "therapy": {
                "id": 8204,
                "therapyName": "TQB3804",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 14950,
                    "pubMedId": null,
                    "title": "Preclinical evaluation of TQB3804, a potent EGFR C797S inhibitor.",
                    "url": "https://www.aacr.org/Documents/AACR_2019_Proceedings.pdf"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 16836,
            "approvalStatus": "Preclinical - Pdx & cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, TQB3804 inhibited Egfr downstream signaling, resulted in growth inhibition of non-small cell lung cancer cell lines harboring EGFR E746_A750del, T790M, and C797S triple mutations in culture and in cell line xenograft models, and inhibited tumor growth in a patient-derived xenograft (PDX) model (Proceedings of the American Association for Cancer Research, Vol 60, Mar 2019, Abstract #1320).",
            "molecularProfile": {
                "id": 11688,
                "profileName": "EGFR E746_A750del EGFR T790M EGFR C797S"
            },
            "therapy": {
                "id": 8204,
                "therapyName": "TQB3804",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 14950,
                    "pubMedId": null,
                    "title": "Preclinical evaluation of TQB3804, a potent EGFR C797S inhibitor.",
                    "url": "https://www.aacr.org/Documents/AACR_2019_Proceedings.pdf"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 3102,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Gilotrif (afatinib) inhibited growth of transformed cells expressing an EGFR E746_A750del/EGFR C797S double mutation in culture (PMID: 25948633).",
            "molecularProfile": {
                "id": 11691,
                "profileName": "EGFR E746_A750del EGFR C797S"
            },
            "therapy": {
                "id": 623,
                "therapyName": "Afatinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 3618,
                    "pubMedId": 25948633,
                    "title": "EGFR Mutations and Resistance to Irreversible Pyrimidine-Based EGFR Inhibitors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25948633"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 10303,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Gilotrif (afatinib) inhibited growth of a non-small cell lung cancer cell line harboring EGFR E746_A750del and expressing EGFR E746_A750del/C797S in culture (PMID: 25948633).",
            "molecularProfile": {
                "id": 11691,
                "profileName": "EGFR E746_A750del EGFR C797S"
            },
            "therapy": {
                "id": 623,
                "therapyName": "Afatinib",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 3618,
                    "pubMedId": 25948633,
                    "title": "EGFR Mutations and Resistance to Irreversible Pyrimidine-Based EGFR Inhibitors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25948633"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 3090,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, transformed cells expressing an EGFR E746_A750del/EGFR C797S double mutation demonstrated resistance to AZD9291 in culture (PMID: 25948633).",
            "molecularProfile": {
                "id": 11691,
                "profileName": "EGFR E746_A750del EGFR C797S"
            },
            "therapy": {
                "id": 660,
                "therapyName": "Osimertinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 3618,
                    "pubMedId": 25948633,
                    "title": "EGFR Mutations and Resistance to Irreversible Pyrimidine-Based EGFR Inhibitors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25948633"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 10301,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, a non-small cell lung cancer cell line harboring EGFR E746_A750del and expressing EGFR E746_A750del/C797S demonstrated resistance to growth inhibition by Tagrisso (osimertinib) in culture (PMID: 25948633).",
            "molecularProfile": {
                "id": 11691,
                "profileName": "EGFR E746_A750del EGFR C797S"
            },
            "therapy": {
                "id": 660,
                "therapyName": "Osimertinib",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 3618,
                    "pubMedId": 25948633,
                    "title": "EGFR Mutations and Resistance to Irreversible Pyrimidine-Based EGFR Inhibitors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25948633"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 3078,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, cells expressing an EGFR E746_A750del/EGFR C797S double mutation demonstrated resistance to Rociletinib (CO-1686) in culture (PMID: 25948633).",
            "molecularProfile": {
                "id": 11691,
                "profileName": "EGFR E746_A750del EGFR C797S"
            },
            "therapy": {
                "id": 1003,
                "therapyName": "Rociletinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 3618,
                    "pubMedId": 25948633,
                    "title": "EGFR Mutations and Resistance to Irreversible Pyrimidine-Based EGFR Inhibitors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25948633"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 10299,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, a non-small cell lung cancer cell line harboring EGFR DelE746_A750 and expressing EGFR DelE746_A750/C797S demonstrated resistance to growth inhibition by Rociletinib (CO1686) in culture (PMID: 25948633).",
            "molecularProfile": {
                "id": 11691,
                "profileName": "EGFR E746_A750del EGFR C797S"
            },
            "therapy": {
                "id": 1003,
                "therapyName": "Rociletinib",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 3618,
                    "pubMedId": 25948633,
                    "title": "EGFR Mutations and Resistance to Irreversible Pyrimidine-Based EGFR Inhibitors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25948633"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 10300,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, a non-small cell lung cancer cell line harboring EGFR E746_A750del and expressing EGFR E746_A750del/C797S demonstrated resistance to growth inhibition by WZ4002 in culture (PMID: 25948633).",
            "molecularProfile": {
                "id": 11691,
                "profileName": "EGFR E746_A750del EGFR C797S"
            },
            "therapy": {
                "id": 3075,
                "therapyName": "WZ4002",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 3618,
                    "pubMedId": 25948633,
                    "title": "EGFR Mutations and Resistance to Irreversible Pyrimidine-Based EGFR Inhibitors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25948633"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 10302,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Iressa (gefitinib) inhibited growth of a non-small cell lung cancer cell line harboring EGFR E746_A750del and expressing EGFR E746_A750del/C797S in culture (PMID: 25948633).",
            "molecularProfile": {
                "id": 11691,
                "profileName": "EGFR E746_A750del EGFR C797S"
            },
            "therapy": {
                "id": 751,
                "therapyName": "Gefitinib",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 3618,
                    "pubMedId": 25948633,
                    "title": "EGFR Mutations and Resistance to Irreversible Pyrimidine-Based EGFR Inhibitors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25948633"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 3080,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, transformed cells expressing an EGFR L858R/EGFR C797S double mutation demonstrated resistance to Rociletinib (CO-1686) in culture (PMID: 25948633).",
            "molecularProfile": {
                "id": 11696,
                "profileName": "EGFR C797S EGFR L858R"
            },
            "therapy": {
                "id": 1003,
                "therapyName": "Rociletinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 3618,
                    "pubMedId": 25948633,
                    "title": "EGFR Mutations and Resistance to Irreversible Pyrimidine-Based EGFR Inhibitors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25948633"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 21251,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Iressa (gefitinib) inhibited growth of transformed cells expressing both EGFR C797S and EGFR L858R in culture (PMID: 29410323).",
            "molecularProfile": {
                "id": 11696,
                "profileName": "EGFR C797S EGFR L858R"
            },
            "therapy": {
                "id": 751,
                "therapyName": "Gefitinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 11558,
                    "pubMedId": 29410323,
                    "title": "EGFR T790M and C797S Mutations as Mechanisms of Acquired Resistance to Dacomitinib.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29410323"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 14783,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, transformed cells expressing EGFR L858R with EGFR C797S demonstrated resistance to inhibition by Poziotinib (HM781-36B) in culture (PMID: 29686424).",
            "molecularProfile": {
                "id": 11696,
                "profileName": "EGFR C797S EGFR L858R"
            },
            "therapy": {
                "id": 1042,
                "therapyName": "Poziotinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 11486,
                    "pubMedId": 29686424,
                    "title": "Mechanisms and clinical activity of an EGFR and HER2 exon 20-selective kinase inhibitor in non-small cell lung cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29686424"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 3103,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Gilotrif (afatinib) inhibited growth of transformed cells expressing an EGFR L858R/EGFR C797S double mutation in culture (PMID: 25948633).",
            "molecularProfile": {
                "id": 11696,
                "profileName": "EGFR C797S EGFR L858R"
            },
            "therapy": {
                "id": 623,
                "therapyName": "Afatinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 3618,
                    "pubMedId": 25948633,
                    "title": "EGFR Mutations and Resistance to Irreversible Pyrimidine-Based EGFR Inhibitors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25948633"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 9989,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, transformed cells expressing EGFR L858R and EGFR C797S demonstrated sensitivity to Tarceva (erlotinib) in culture (PMID: 27913578).",
            "molecularProfile": {
                "id": 11696,
                "profileName": "EGFR C797S EGFR L858R"
            },
            "therapy": {
                "id": 4,
                "therapyName": "Erlotinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 7760,
                    "pubMedId": 27913578,
                    "title": "Characterization of EGFR T790M, L792F, and C797S Mutations as Mechanisms of Acquired Resistance to Afatinib in Lung Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27913578"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 21250,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Tarceva (erlotinib) inhibited growth of transformed cells expressing both EGFR C797S and EGFR L858R in culture (PMID: 29410323).",
            "molecularProfile": {
                "id": 11696,
                "profileName": "EGFR C797S EGFR L858R"
            },
            "therapy": {
                "id": 4,
                "therapyName": "Erlotinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 11558,
                    "pubMedId": 29410323,
                    "title": "EGFR T790M and C797S Mutations as Mechanisms of Acquired Resistance to Dacomitinib.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29410323"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 3091,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, transformed cells expressing an EGFR L858R/EGFR C797S double mutation demonstrated resistance to AZD9291 in culture (PMID: 25948633).",
            "molecularProfile": {
                "id": 11696,
                "profileName": "EGFR C797S EGFR L858R"
            },
            "therapy": {
                "id": 660,
                "therapyName": "Osimertinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 3618,
                    "pubMedId": 25948633,
                    "title": "EGFR Mutations and Resistance to Irreversible Pyrimidine-Based EGFR Inhibitors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25948633"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 21242,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, EGFR C797S was identified in 11.4% (4/35) of Vizimpro (dacomitinib)-resistant clones generated through ENU mutagenesis in transformed cells expressing EGFR L858R (PMID: 29410323).",
            "molecularProfile": {
                "id": 11696,
                "profileName": "EGFR C797S EGFR L858R"
            },
            "therapy": {
                "id": 714,
                "therapyName": "Dacomitinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "predicted - resistant",
            "references": [
                {
                    "id": 11558,
                    "pubMedId": 29410323,
                    "title": "EGFR T790M and C797S Mutations as Mechanisms of Acquired Resistance to Dacomitinib.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29410323"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 18675,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, JBJ-04-125-02 inhibited proliferation of a transformed mouse cell line expressing EGFR C797S and L858R in culture, however, with decreased response compared to cells treated with Iressa (gefitinib) (PMID: 31092401).",
            "molecularProfile": {
                "id": 11696,
                "profileName": "EGFR C797S EGFR L858R"
            },
            "therapy": {
                "id": 8684,
                "therapyName": "JBJ-04-125-02",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "decreased response",
            "references": [
                {
                    "id": 16071,
                    "pubMedId": 31092401,
                    "title": "Single and Dual Targeting of Mutant EGFR with an Allosteric Inhibitor.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31092401"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 15869,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I trial, a lung adenocarcinoma patient harboring an EGFR exon 19 deletion and EGFR T790M demonstrated an initial partial response to treatment with Nazartinib (CO-1686), however, demonstrated progression in the liver followed by the thorax, and progression in the thorax was coincident with emergence of an EGFR C797S mutation (PMID: 30123863; NCT02108964).",
            "molecularProfile": {
                "id": 14858,
                "profileName": "EGFR exon 19 del EGFR T790M EGFR C797S"
            },
            "therapy": {
                "id": 1309,
                "therapyName": "Nazartinib",
                "synonyms": null
            },
            "indication": {
                "id": 3910,
                "name": "lung adenocarcinoma",
                "source": "DOID"
            },
            "responseType": "predicted - resistant",
            "references": [
                {
                    "id": 13872,
                    "pubMedId": 30123863,
                    "title": "Heterogeneity and Coexistence of T790M and T790 Wild-Type Resistant Subclones Drive Mixed Response to Third-Generation Epidermal Growth Factor Receptor Inhibitors in Lung Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30123863"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 5759,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, lung adenocarcinoma cells over expressing EGFR exon 19 deletion, EGFR T790M and EGFR C797S in cis were resistant to WZ4002 induced suppression of EGFR signaling and growth inhibition in culture (PMID: 25964297).",
            "molecularProfile": {
                "id": 14858,
                "profileName": "EGFR exon 19 del EGFR T790M EGFR C797S"
            },
            "therapy": {
                "id": 3075,
                "therapyName": "WZ4002",
                "synonyms": null
            },
            "indication": {
                "id": 3910,
                "name": "lung adenocarcinoma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 3620,
                    "pubMedId": 25964297,
                    "title": "The Allelic Context of the C797S Mutation Acquired upon Treatment with Third-Generation EGFR Inhibitors Impacts Sensitivity to Subsequent Treatment Strategies.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25964297"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 5756,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Iressa (gefitinib) and WZ4002 combination treatment resulted in complete inhibition of EGFR signaling in transformed human cells over expressing EGFR exon 19 deletion, EGFR T790M and EGFR C797S when T790M and C797S were expressed in trans, but no EGFR inhibition when T790M and C797S were expressed in cis (PMID: 25964297).",
            "molecularProfile": {
                "id": 14858,
                "profileName": "EGFR exon 19 del EGFR T790M EGFR C797S"
            },
            "therapy": {
                "id": 3921,
                "therapyName": "Gefitinib + WZ4002",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "conflicting",
            "references": [
                {
                    "id": 3620,
                    "pubMedId": 25964297,
                    "title": "The Allelic Context of the C797S Mutation Acquired upon Treatment with Third-Generation EGFR Inhibitors Impacts Sensitivity to Subsequent Treatment Strategies.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25964297"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 17664,
            "approvalStatus": "Preclinical - Patient cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Lazertinib (YH25448) did not inhibit viability of patient-derived non-small cell lung cancer cells harboring EGFR C797S, EGFR exon 19 deletion, and EGFR T790M (PMID: 30670498).",
            "molecularProfile": {
                "id": 14858,
                "profileName": "EGFR exon 19 del EGFR T790M EGFR C797S"
            },
            "therapy": {
                "id": 8558,
                "therapyName": "Lazertinib",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 15689,
                    "pubMedId": 30670498,
                    "title": "YH25448, an Irreversible EGFR-TKI with Potent Intracranial Activity in EGFR Mutant Non-Small Cell Lung Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30670498"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 15874,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical case study, EGFR C797S was identified as an acquired mutation in a patient with lung adenocarcinoma harboring EGFR exon 19 deletion and T790M at disease progression while on Olmutinib (HM61713) treatment (PMID: 26749488).",
            "molecularProfile": {
                "id": 14858,
                "profileName": "EGFR exon 19 del EGFR T790M EGFR C797S"
            },
            "therapy": {
                "id": 2137,
                "therapyName": "Olmutinib",
                "synonyms": null
            },
            "indication": {
                "id": 3910,
                "name": "lung adenocarcinoma",
                "source": "DOID"
            },
            "responseType": "predicted - resistant",
            "references": [
                {
                    "id": 13881,
                    "pubMedId": 26749488,
                    "title": "Acquired C797S Mutation upon Treatment with a T790M-Specific Third-Generation EGFR Inhibitor (HM61713) in Non-Small Cell Lung Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26749488"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 5746,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, non-small cell lung carcinoma cells harboring EGFR exon 19 deletion, EGFR T790M and EGFR C797S in cis were resistant to Gilotrif (afatinib) induced suppression of EGFR signaling and growth inhibition in culture (PMID: 25964297).",
            "molecularProfile": {
                "id": 14858,
                "profileName": "EGFR exon 19 del EGFR T790M EGFR C797S"
            },
            "therapy": {
                "id": 623,
                "therapyName": "Afatinib",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 3620,
                    "pubMedId": 25964297,
                    "title": "The Allelic Context of the C797S Mutation Acquired upon Treatment with Third-Generation EGFR Inhibitors Impacts Sensitivity to Subsequent Treatment Strategies.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25964297"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 5760,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, lung adenocarcinoma cells over expressing EGFR exon 19 deletion, EGFR T790M and EGFR C797S in cis were resistant to Gilotrif (afatinib) induced suppression of EGFR signaling and growth inhibition in culture (PMID: 25964297).",
            "molecularProfile": {
                "id": 14858,
                "profileName": "EGFR exon 19 del EGFR T790M EGFR C797S"
            },
            "therapy": {
                "id": 623,
                "therapyName": "Afatinib",
                "synonyms": null
            },
            "indication": {
                "id": 3910,
                "name": "lung adenocarcinoma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 3620,
                    "pubMedId": 25964297,
                    "title": "The Allelic Context of the C797S Mutation Acquired upon Treatment with Third-Generation EGFR Inhibitors Impacts Sensitivity to Subsequent Treatment Strategies.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25964297"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 5755,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, WZ4002 treatment resulted in partial inhibition of EGFR signaling in transformed human cells over expressing EGFR exon 19 deletion, EGFR T790M and EGFR C797S when T790M and C797S were expressed in trans, but no EGFR inhibition when T790M and C797S were expressed in cis (PMID: 25964297).",
            "molecularProfile": {
                "id": 14858,
                "profileName": "EGFR exon 19 del EGFR T790M EGFR C797S"
            },
            "therapy": {
                "id": 3075,
                "therapyName": "WZ4002",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "conflicting",
            "references": [
                {
                    "id": 3620,
                    "pubMedId": 25964297,
                    "title": "The Allelic Context of the C797S Mutation Acquired upon Treatment with Third-Generation EGFR Inhibitors Impacts Sensitivity to Subsequent Treatment Strategies.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25964297"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 20697,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical study, EGFR C797S was detected in non-small cell lung cancer patients harboring EGFR exon 19 deletions and EGFR T790M with acquired resistance to Tagrisso (osimertinib) (PMID: 31911548).",
            "molecularProfile": {
                "id": 14858,
                "profileName": "EGFR exon 19 del EGFR T790M EGFR C797S"
            },
            "therapy": {
                "id": 660,
                "therapyName": "Osimertinib",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 17999,
                    "pubMedId": 31911548,
                    "title": "Tumor Analyses Reveal Squamous Transformation and Off-Target Alterations As Early Resistance Mechanisms to First-line Osimertinib in EGFR-Mutant Lung Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31911548"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 15498,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical study, acquired EGFR C797S mutations were identified in post-treatment samples of 6 non-small cell lung cancer patients harboring EGFR exon 19 deletions and EGFR T790M who progressed on Tagrisso (osimertinib) (PMID: 30228210).",
            "molecularProfile": {
                "id": 14858,
                "profileName": "EGFR exon 19 del EGFR T790M EGFR C797S"
            },
            "therapy": {
                "id": 660,
                "therapyName": "Osimertinib",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 13403,
                    "pubMedId": 30228210,
                    "title": "Landscape of EGFR-Dependent and -Independent Resistance Mechanisms to Osimertinib and Continuation Therapy Beyond Progression in EGFR-Mutant NSCLC.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30228210"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 18135,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, non-small cell lung cancer cells harboring EGFR C797S, EGFR T790M and EGFR exon 19 deletion mutations in-cis were resistant to Tagrisso (osimertinib) in culture (PMID: 30962319).",
            "molecularProfile": {
                "id": 14858,
                "profileName": "EGFR exon 19 del EGFR T790M EGFR C797S"
            },
            "therapy": {
                "id": 660,
                "therapyName": "Osimertinib",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 16007,
                    "pubMedId": 30962319,
                    "title": "Discovery of A Novel EGFR-Targeting Antibody-Drug Conjugate, SHR-A1307, for the Treatment of Solid Tumors Resistant or Refractory to Anti-EGFR Therapies.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30962319"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 3692,
            "approvalStatus": "Phase I",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I clinical trial, 40% (6/15) of non-small cell lung cancer patients harboring an EGFR exon 19 deletion and EGFR T790M developed resistance to Tagrisso (osimertinib) due to acquired EGFR C797S mutations (PMID: 25939061).",
            "molecularProfile": {
                "id": 14858,
                "profileName": "EGFR exon 19 del EGFR T790M EGFR C797S"
            },
            "therapy": {
                "id": 660,
                "therapyName": "Osimertinib",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 3996,
                    "pubMedId": 25939061,
                    "title": "Acquired EGFR C797S mutation mediates resistance to AZD9291 in non-small cell lung cancer harboring EGFR T790M.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25939061"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 3694,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, expression of EGFR C797S on the same allele as an EGFR exon 19 deletion and EGFR T790M in transformed cell lines resulted in resistance to growth inhibition by Tagrisso (osimertinib) in culture (PMID: 25939061).",
            "molecularProfile": {
                "id": 14858,
                "profileName": "EGFR exon 19 del EGFR T790M EGFR C797S"
            },
            "therapy": {
                "id": 660,
                "therapyName": "Osimertinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 3996,
                    "pubMedId": 25939061,
                    "title": "Acquired EGFR C797S mutation mediates resistance to AZD9291 in non-small cell lung cancer harboring EGFR T790M.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25939061"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 5758,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, lung adenocarcinoma cells over expressing EGFR exon 19 deletion, EGFR T790M and EGFR C797S in cis were resistant to Iressa (gefitinib) induced suppression of EGFR signaling and growth inhibition in culture (PMID: 25964297).",
            "molecularProfile": {
                "id": 14858,
                "profileName": "EGFR exon 19 del EGFR T790M EGFR C797S"
            },
            "therapy": {
                "id": 751,
                "therapyName": "Gefitinib",
                "synonyms": null
            },
            "indication": {
                "id": 3910,
                "name": "lung adenocarcinoma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 3620,
                    "pubMedId": 25964297,
                    "title": "The Allelic Context of the C797S Mutation Acquired upon Treatment with Third-Generation EGFR Inhibitors Impacts Sensitivity to Subsequent Treatment Strategies.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25964297"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 5745,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, non-small cell lung carcinoma cells harboring EGFR exon 19 deletion, EGFR T790M and EGFR C797S were resistant to WZ4002 induced suppression of EGFR signaling and growth inhibition in culture, regardless of the allelic context of EGFR T790M and EGFR C797S (PMID: 25964297).",
            "molecularProfile": {
                "id": 14858,
                "profileName": "EGFR exon 19 del EGFR T790M EGFR C797S"
            },
            "therapy": {
                "id": 3075,
                "therapyName": "WZ4002",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 3620,
                    "pubMedId": 25964297,
                    "title": "The Allelic Context of the C797S Mutation Acquired upon Treatment with Third-Generation EGFR Inhibitors Impacts Sensitivity to Subsequent Treatment Strategies.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25964297"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 5754,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Iressa (gefitinib) treatment resulted in partial inhibition of EGFR signaling in transformed human cells over expressing EGFR exon 19 deletion, EGFR T790M and EGFR C797S when T790M and C797S were expressed in trans, but no EGFR inhibition when T790M and C797S were expressed in cis (PMID: 25964297).",
            "molecularProfile": {
                "id": 14858,
                "profileName": "EGFR exon 19 del EGFR T790M EGFR C797S"
            },
            "therapy": {
                "id": 751,
                "therapyName": "Gefitinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "conflicting",
            "references": [
                {
                    "id": 3620,
                    "pubMedId": 25964297,
                    "title": "The Allelic Context of the C797S Mutation Acquired upon Treatment with Third-Generation EGFR Inhibitors Impacts Sensitivity to Subsequent Treatment Strategies.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25964297"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 5757,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, transformed human cells over expressing EGFR exon 19 deletion, EGFR T790M and EGFR C797S in cis were resistant to Gilotrif (afatinib) induced suppression of EGFR signaling in culture (PMID: 25964297).",
            "molecularProfile": {
                "id": 14858,
                "profileName": "EGFR exon 19 del EGFR T790M EGFR C797S"
            },
            "therapy": {
                "id": 623,
                "therapyName": "Afatinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 3620,
                    "pubMedId": 25964297,
                    "title": "The Allelic Context of the C797S Mutation Acquired upon Treatment with Third-Generation EGFR Inhibitors Impacts Sensitivity to Subsequent Treatment Strategies.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25964297"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 18134,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, non-small cell lung cancer cells harboring EGFR C797S, EGFR T790M and EGFR exon 19 deletion mutations in-cis demonstrated inhibition of cell growth in culture following treatment with Tarceva (erlotinib) (PMID: 30962319).",
            "molecularProfile": {
                "id": 14858,
                "profileName": "EGFR exon 19 del EGFR T790M EGFR C797S"
            },
            "therapy": {
                "id": 4,
                "therapyName": "Erlotinib",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 16007,
                    "pubMedId": 30962319,
                    "title": "Discovery of A Novel EGFR-Targeting Antibody-Drug Conjugate, SHR-A1307, for the Treatment of Solid Tumors Resistant or Refractory to Anti-EGFR Therapies.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30962319"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 3695,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, EGFR C797S conferred resistance to growth inhibition by Rociletinib (CO-1686) when expressed on the same allele as an EGFR exon 19 deletion mutation and T790M in transformed cells in culture (PMID: 25939061).",
            "molecularProfile": {
                "id": 14858,
                "profileName": "EGFR exon 19 del EGFR T790M EGFR C797S"
            },
            "therapy": {
                "id": 1003,
                "therapyName": "Rociletinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 3996,
                    "pubMedId": 25939061,
                    "title": "Acquired EGFR C797S mutation mediates resistance to AZD9291 in non-small cell lung cancer harboring EGFR T790M.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25939061"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 18133,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, non-small cell lung cancer cells harboring EGFR C797S, EGFR T790M and EGFR exon 19 deletion mutations in-cis demonstrated inhibition of cell growth in culture, and reduction of tumor volume and remission in xenograft models following treatment with SHR-A1307 (PMID: 30962319).",
            "molecularProfile": {
                "id": 14858,
                "profileName": "EGFR exon 19 del EGFR T790M EGFR C797S"
            },
            "therapy": {
                "id": 8671,
                "therapyName": "SHR-A1307",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 16007,
                    "pubMedId": 30962319,
                    "title": "Discovery of A Novel EGFR-Targeting Antibody-Drug Conjugate, SHR-A1307, for the Treatment of Solid Tumors Resistant or Refractory to Anti-EGFR Therapies.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30962319"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 5747,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, non-small cell lung carcinoma cells harboring EGFR exon 19 deletion, EGFR T790M and EGFR C797S were resistant to the combination of Iressa (gefitinib) and WZ4002 when T790M and C797S were in cis, but were sensitive when EGFR T790M and EGFR C797S were in trans (PMID: 25964297).",
            "molecularProfile": {
                "id": 14858,
                "profileName": "EGFR exon 19 del EGFR T790M EGFR C797S"
            },
            "therapy": {
                "id": 3921,
                "therapyName": "Gefitinib + WZ4002",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "conflicting",
            "references": [
                {
                    "id": 3620,
                    "pubMedId": 25964297,
                    "title": "The Allelic Context of the C797S Mutation Acquired upon Treatment with Third-Generation EGFR Inhibitors Impacts Sensitivity to Subsequent Treatment Strategies.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25964297"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 5744,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, non-small cell lung carcinoma cells harboring EGFR exon 19 deletion, EGFR T790M and EGFR C797S were resistant to Iressa (gefitinib) induced suppression of EGFR signaling and growth inhibition in culture, regardless of the allelic context of EGFR T790M and EGFR C797S (PMID: 25964297).",
            "molecularProfile": {
                "id": 14858,
                "profileName": "EGFR exon 19 del EGFR T790M EGFR C797S"
            },
            "therapy": {
                "id": 751,
                "therapyName": "Gefitinib",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 3620,
                    "pubMedId": 25964297,
                    "title": "The Allelic Context of the C797S Mutation Acquired upon Treatment with Third-Generation EGFR Inhibitors Impacts Sensitivity to Subsequent Treatment Strategies.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25964297"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 18288,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, transformed cells co-expressing EGFR L858R and EGFR C797S in culture demonstrated resistance to treatment with Iressa (gefitinib) after 3 weeks of exposure, and subsequently, were found to have acquired EGFR T790M (PMID: 31377341).",
            "molecularProfile": {
                "id": 14859,
                "profileName": "EGFR T790M EGFR C797S EGFR L858R"
            },
            "therapy": {
                "id": 751,
                "therapyName": "Gefitinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "predicted - resistant",
            "references": [
                {
                    "id": 16121,
                    "pubMedId": 31377341,
                    "title": "EGFR-Mutated Lung Cancers Resistant to Osimertinib through EGFR C797S Respond to First-Generation Reversible EGFR Inhibitors but Eventually Acquire EGFR T790M/C797S in Preclinical Models and Clinical Samples.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31377341"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 7596,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, EAI045 and Erbitux (cetuximab) combination treatment induced tumor regression in an EGFR L858R/T790M/C797S-mutant-driven lung cancer mouse model (PMID: 27251290).",
            "molecularProfile": {
                "id": 14859,
                "profileName": "EGFR T790M EGFR C797S EGFR L858R"
            },
            "therapy": {
                "id": 4521,
                "therapyName": "Cetuximab + EAI045",
                "synonyms": null
            },
            "indication": {
                "id": 1324,
                "name": "lung cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6436,
                    "pubMedId": 27251290,
                    "title": "Overcoming EGFR(T790M) and EGFR(C797S) resistance with mutant-selective allosteric inhibitors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27251290"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 12630,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, overexpression of EGFR C797S in addition to EGFR L858R and T790M conferred resistance to Nazartinib (EGF816) in transformed cells in culture (PMID: 29285266)",
            "molecularProfile": {
                "id": 14859,
                "profileName": "EGFR T790M EGFR C797S EGFR L858R"
            },
            "therapy": {
                "id": 1309,
                "therapyName": "Nazartinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 10505,
                    "pubMedId": 29285266,
                    "title": "Characterization of the efficacies of osimertinib and nazartinib against cells expressing clinically relevant epidermal growth factor receptor mutations.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29285266"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 14492,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, transformed cells co-expressing EGFR C797S, EGFR L858R, and EGFR T790M did not respond to treatment with OBX1-012 in culture (PMID: 29754184).",
            "molecularProfile": {
                "id": 14859,
                "profileName": "EGFR T790M EGFR C797S EGFR L858R"
            },
            "therapy": {
                "id": 7094,
                "therapyName": "OBX1-012",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "predicted - resistant",
            "references": [
                {
                    "id": 11644,
                    "pubMedId": 29754184,
                    "title": "Discovery of a Potent and Mutant-Selective EGFR Inhibitor that Overcomes T790M-Mediated Resistance in Lung Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29754184"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 3697,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, EGFR C797S conferred resistance to growth inhibition by Rociletinib (CO-1686) when expressed on the same allele as EGFR L858R and T790M in transformed cells in culture (PMID: 25939061).",
            "molecularProfile": {
                "id": 14859,
                "profileName": "EGFR T790M EGFR C797S EGFR L858R"
            },
            "therapy": {
                "id": 1003,
                "therapyName": "Rociletinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 3996,
                    "pubMedId": 25939061,
                    "title": "Acquired EGFR C797S mutation mediates resistance to AZD9291 in non-small cell lung cancer harboring EGFR T790M.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25939061"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 12632,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, overexpression of EGFR C797S in addition to EGFR L858R and T790M conferred resistance to Tarceva (erlotinib) in transformed cells in culture (PMID: 29285266)",
            "molecularProfile": {
                "id": 14859,
                "profileName": "EGFR T790M EGFR C797S EGFR L858R"
            },
            "therapy": {
                "id": 4,
                "therapyName": "Erlotinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 10505,
                    "pubMedId": 29285266,
                    "title": "Characterization of the efficacies of osimertinib and nazartinib against cells expressing clinically relevant epidermal growth factor receptor mutations.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29285266"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 10304,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Erbitux (cetuximab) inhibited growth of transformed cells expressing a EGFR L858R/T790M/C797S triple mutation in culture (PMID: 25948633).",
            "molecularProfile": {
                "id": 14859,
                "profileName": "EGFR T790M EGFR C797S EGFR L858R"
            },
            "therapy": {
                "id": 694,
                "therapyName": "Cetuximab",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 3618,
                    "pubMedId": 25948633,
                    "title": "EGFR Mutations and Resistance to Irreversible Pyrimidine-Based EGFR Inhibitors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25948633"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 18666,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, JBJ-04-125-02 induced tumor regression in a transgenic mouse model of lung cancer harboring EGFR L858R, T790M and C797S (PMID: 31092401).",
            "molecularProfile": {
                "id": 14859,
                "profileName": "EGFR T790M EGFR C797S EGFR L858R"
            },
            "therapy": {
                "id": 8684,
                "therapyName": "JBJ-04-125-02",
                "synonyms": null
            },
            "indication": {
                "id": 1324,
                "name": "lung cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 16071,
                    "pubMedId": 31092401,
                    "title": "Single and Dual Targeting of Mutant EGFR with an Allosteric Inhibitor.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31092401"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 12631,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, overexpression of EGFR C797S in addition to EGFR L858R and T790M conferred resistance to Gilotrif (afatinib) in transformed cells in culture (PMID: 29285266).",
            "molecularProfile": {
                "id": 14859,
                "profileName": "EGFR T790M EGFR C797S EGFR L858R"
            },
            "therapy": {
                "id": 623,
                "therapyName": "Afatinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 10505,
                    "pubMedId": 29285266,
                    "title": "Characterization of the efficacies of osimertinib and nazartinib against cells expressing clinically relevant epidermal growth factor receptor mutations.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29285266"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 13628,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, transformed cells expressing a combination of EGFR C797S, EGFR L858R, and EGFR T790M were resistant to Naquotinib (ASP8273) in culture (PMID: 29467275).",
            "molecularProfile": {
                "id": 14859,
                "profileName": "EGFR T790M EGFR C797S EGFR L858R"
            },
            "therapy": {
                "id": 1082,
                "therapyName": "Naquotinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 11222,
                    "pubMedId": 29467275,
                    "title": "Pharmacological and Structural Characterizations of Naquotinib, a Novel Third-Generation EGFR Tyrosine Kinase Inhibitor, in EGFR-Mutated Non-Small Cell Lung Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29467275"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 18660,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, JBJ-04-125-02 inhibited proliferation of a transformed mouse cell line expressing EGFR L858R, C797S, and T790M in culture (PMID: 31092401).",
            "molecularProfile": {
                "id": 14859,
                "profileName": "EGFR T790M EGFR C797S EGFR L858R"
            },
            "therapy": {
                "id": 8684,
                "therapyName": "JBJ-04-125-02",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 16071,
                    "pubMedId": 31092401,
                    "title": "Single and Dual Targeting of Mutant EGFR with an Allosteric Inhibitor.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31092401"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 18674,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, JBJ-04-125-02 and Erbitux (cetuximab) combination treatment inhibited proliferation of a transformed mouse cell line expressing EGFR L858R, C797S, and T790M in culture (PMID: 31092401).",
            "molecularProfile": {
                "id": 14859,
                "profileName": "EGFR T790M EGFR C797S EGFR L858R"
            },
            "therapy": {
                "id": 8807,
                "therapyName": "Cetuximab + JBJ-04-125-02",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 16071,
                    "pubMedId": 31092401,
                    "title": "Single and Dual Targeting of Mutant EGFR with an Allosteric Inhibitor.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31092401"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 18136,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, non-small cell lung cancer cells harboring EGFR C797S, EGFR L858R and EGFR exon 19 deletion mutations in-cis demonstrated inhibition of cell growth in culture following treatment with SHR-A1307 (PMID: 30962319).",
            "molecularProfile": {
                "id": 14859,
                "profileName": "EGFR T790M EGFR C797S EGFR L858R"
            },
            "therapy": {
                "id": 8671,
                "therapyName": "SHR-A1307",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 16007,
                    "pubMedId": 30962319,
                    "title": "Discovery of A Novel EGFR-Targeting Antibody-Drug Conjugate, SHR-A1307, for the Treatment of Solid Tumors Resistant or Refractory to Anti-EGFR Therapies.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30962319"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 7597,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, EAI045 and Erbitux (cetuximab) synergistically inhibited proliferation of transformed cells over expressing EGFR that harbors concomitant C797S, L858R and T790M mutations in culture (PMID: 27251290).",
            "molecularProfile": {
                "id": 14859,
                "profileName": "EGFR T790M EGFR C797S EGFR L858R"
            },
            "therapy": {
                "id": 4521,
                "therapyName": "Cetuximab + EAI045",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6436,
                    "pubMedId": 27251290,
                    "title": "Overcoming EGFR(T790M) and EGFR(C797S) resistance with mutant-selective allosteric inhibitors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27251290"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 18670,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, EAI045 and Erbitux (cetuximab) combination treatment inhibited proliferation of a transformed mouse cell line expressing EGFR L858R, C797S, and T790M in culture (PMID: 31092401).",
            "molecularProfile": {
                "id": 14859,
                "profileName": "EGFR T790M EGFR C797S EGFR L858R"
            },
            "therapy": {
                "id": 4521,
                "therapyName": "Cetuximab + EAI045",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 16071,
                    "pubMedId": 31092401,
                    "title": "Single and Dual Targeting of Mutant EGFR with an Allosteric Inhibitor.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31092401"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 18137,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, non-small cell lung cancer cells harboring EGFR C797S, EGFR L858R and EGFR exon 19 deletion mutations in-cis were resistant to Tagrisso (osimertinib) in culture (PMID: 30962319).",
            "molecularProfile": {
                "id": 14859,
                "profileName": "EGFR T790M EGFR C797S EGFR L858R"
            },
            "therapy": {
                "id": 660,
                "therapyName": "Osimertinib",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 16007,
                    "pubMedId": 30962319,
                    "title": "Discovery of A Novel EGFR-Targeting Antibody-Drug Conjugate, SHR-A1307, for the Treatment of Solid Tumors Resistant or Refractory to Anti-EGFR Therapies.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30962319"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 3696,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, expression of EGFR C797S on the same allele as both EGFR L858R and T790M in transformed cell lines resulted in resistance to growth inhibition by Tagrisso (osimertinib) in culture (PMID: 25939061).",
            "molecularProfile": {
                "id": 14859,
                "profileName": "EGFR T790M EGFR C797S EGFR L858R"
            },
            "therapy": {
                "id": 660,
                "therapyName": "Osimertinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 3996,
                    "pubMedId": 25939061,
                    "title": "Acquired EGFR C797S mutation mediates resistance to AZD9291 in non-small cell lung cancer harboring EGFR T790M.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25939061"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 5752,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Gilotrif (afatinib) inhibited EGFR signaling in transformed human cells over expressing EGFR exon 19 deletion and EGFR C797S in culture (PMID: 25964297).",
            "molecularProfile": {
                "id": 21570,
                "profileName": "EGFR exon 19 del EGFR C797S"
            },
            "therapy": {
                "id": 623,
                "therapyName": "Afatinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 3620,
                    "pubMedId": 25964297,
                    "title": "The Allelic Context of the C797S Mutation Acquired upon Treatment with Third-Generation EGFR Inhibitors Impacts Sensitivity to Subsequent Treatment Strategies.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25964297"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 5762,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Iressa (gefitinib) inhibited EGFR signaling and cell growth in lung adenocarcinoma cells over expressing EGFR exon 19 deletion and EGFR C797S in culture (PMID: 25964297).",
            "molecularProfile": {
                "id": 21570,
                "profileName": "EGFR exon 19 del EGFR C797S"
            },
            "therapy": {
                "id": 623,
                "therapyName": "Afatinib",
                "synonyms": null
            },
            "indication": {
                "id": 3910,
                "name": "lung adenocarcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 3620,
                    "pubMedId": 25964297,
                    "title": "The Allelic Context of the C797S Mutation Acquired upon Treatment with Third-Generation EGFR Inhibitors Impacts Sensitivity to Subsequent Treatment Strategies.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25964297"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 5751,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Iressa (gefitinib) inhibited EGFR signaling in transformed human cells over expressing EGFR exon 19 deletion and EGFR C797S in culture (PMID: 25964297).",
            "molecularProfile": {
                "id": 21570,
                "profileName": "EGFR exon 19 del EGFR C797S"
            },
            "therapy": {
                "id": 751,
                "therapyName": "Gefitinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 3620,
                    "pubMedId": 25964297,
                    "title": "The Allelic Context of the C797S Mutation Acquired upon Treatment with Third-Generation EGFR Inhibitors Impacts Sensitivity to Subsequent Treatment Strategies.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25964297"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 5761,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Iressa (gefitinib) inhibited EGFR signaling and cell growth in lung adenocarcinoma cells over expressing EGFR exon 19 deletion and EGFR C797S in culture (PMID: 25964297).",
            "molecularProfile": {
                "id": 21570,
                "profileName": "EGFR exon 19 del EGFR C797S"
            },
            "therapy": {
                "id": 751,
                "therapyName": "Gefitinib",
                "synonyms": null
            },
            "indication": {
                "id": 3910,
                "name": "lung adenocarcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 3620,
                    "pubMedId": 25964297,
                    "title": "The Allelic Context of the C797S Mutation Acquired upon Treatment with Third-Generation EGFR Inhibitors Impacts Sensitivity to Subsequent Treatment Strategies.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25964297"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 5763,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, lung adenocarcinoma cells over expressing EGFR exon 19 deletion and EGFR C797S were resistant to WZ4002 induced suppression of EGFR signaling and growth inhibition in culture (PMID: 25964297).",
            "molecularProfile": {
                "id": 21570,
                "profileName": "EGFR exon 19 del EGFR C797S"
            },
            "therapy": {
                "id": 3075,
                "therapyName": "WZ4002",
                "synonyms": null
            },
            "indication": {
                "id": 3910,
                "name": "lung adenocarcinoma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 3620,
                    "pubMedId": 25964297,
                    "title": "The Allelic Context of the C797S Mutation Acquired upon Treatment with Third-Generation EGFR Inhibitors Impacts Sensitivity to Subsequent Treatment Strategies.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25964297"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 14761,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, transformed cells expressing an EGFR exon 19 deletion with EGFR C797S demonstrated resistance to inhibition by Poziotinib (HM781-36B) in culture (PMID: 29686424).",
            "molecularProfile": {
                "id": 21570,
                "profileName": "EGFR exon 19 del EGFR C797S"
            },
            "therapy": {
                "id": 1042,
                "therapyName": "Poziotinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 11486,
                    "pubMedId": 29686424,
                    "title": "Mechanisms and clinical activity of an EGFR and HER2 exon 20-selective kinase inhibitor in non-small cell lung cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29686424"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 5753,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, transformed human cells harboring EGFR exon 19 deletion and EGFR C797S were resistant to WZ4002 induced suppression of EGFR signaling in culture (PMID: 25964297).",
            "molecularProfile": {
                "id": 21570,
                "profileName": "EGFR exon 19 del EGFR C797S"
            },
            "therapy": {
                "id": 3075,
                "therapyName": "WZ4002",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 3620,
                    "pubMedId": 25964297,
                    "title": "The Allelic Context of the C797S Mutation Acquired upon Treatment with Third-Generation EGFR Inhibitors Impacts Sensitivity to Subsequent Treatment Strategies.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25964297"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 10511,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, transformed cells expressing an EGFR D770delinsGY/EGFR C797S double mutation demonstrated resistance to Gilotrif (afatinib) in culture (PMID: 28363995).",
            "molecularProfile": {
                "id": 27534,
                "profileName": "EGFR D770delinsGY EGFR C797S"
            },
            "therapy": {
                "id": 623,
                "therapyName": "Afatinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 8567,
                    "pubMedId": 28363995,
                    "title": "Response Heterogeneity of EGFR and HER2 Exon 20 Insertions to Covalent EGFR and HER2 Inhibitors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28363995"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 10510,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, transformed cells expressing an EGFR D770delinsGY and EGFR C797S double mutation demonstrated resistance to Vizimpro (dacomitinib) in culture (PMID: 28363995).",
            "molecularProfile": {
                "id": 27534,
                "profileName": "EGFR D770delinsGY EGFR C797S"
            },
            "therapy": {
                "id": 714,
                "therapyName": "Dacomitinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 8567,
                    "pubMedId": 28363995,
                    "title": "Response Heterogeneity of EGFR and HER2 Exon 20 Insertions to Covalent EGFR and HER2 Inhibitors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28363995"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 12634,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, overexpression of EGFR C797S in addition to EGFR L747_P753delinsS and T790M conferred resistance to Gilotrif (afatinib) in transformed cells in culture (PMID: 29285266).",
            "molecularProfile": {
                "id": 28797,
                "profileName": "EGFR L747_P753delinsS EGFR T790M EGFR C797S"
            },
            "therapy": {
                "id": 623,
                "therapyName": "Afatinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 10505,
                    "pubMedId": 29285266,
                    "title": "Characterization of the efficacies of osimertinib and nazartinib against cells expressing clinically relevant epidermal growth factor receptor mutations.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29285266"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 12636,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, overexpression of EGFR C797S in addition to EGFR L747_P753delinsS and T790M conferred resistance to Nazartinib (EGF816) in transformed cells in culture (PMID: 29285266).",
            "molecularProfile": {
                "id": 28797,
                "profileName": "EGFR L747_P753delinsS EGFR T790M EGFR C797S"
            },
            "therapy": {
                "id": 1309,
                "therapyName": "Nazartinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 10505,
                    "pubMedId": 29285266,
                    "title": "Characterization of the efficacies of osimertinib and nazartinib against cells expressing clinically relevant epidermal growth factor receptor mutations.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29285266"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 12635,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, overexpression of EGFR C797S in addition to EGFR L747_P753delinsS and T790M conferred resistance to Tagrisso (osimertinib) in transformed cells in culture (PMID: 29285266).",
            "molecularProfile": {
                "id": 28797,
                "profileName": "EGFR L747_P753delinsS EGFR T790M EGFR C797S"
            },
            "therapy": {
                "id": 660,
                "therapyName": "Osimertinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 10505,
                    "pubMedId": 29285266,
                    "title": "Characterization of the efficacies of osimertinib and nazartinib against cells expressing clinically relevant epidermal growth factor receptor mutations.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29285266"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 13627,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, transformed cells expressing a combination of EGFR C797S, EGFR L747_P753delinsS, and EGFR T790M were resistant to Naquotinib (ASP8273) in culture (PMID: 29467275).",
            "molecularProfile": {
                "id": 28797,
                "profileName": "EGFR L747_P753delinsS EGFR T790M EGFR C797S"
            },
            "therapy": {
                "id": 1082,
                "therapyName": "Naquotinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 11222,
                    "pubMedId": 29467275,
                    "title": "Pharmacological and Structural Characterizations of Naquotinib, a Novel Third-Generation EGFR Tyrosine Kinase Inhibitor, in EGFR-Mutated Non-Small Cell Lung Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29467275"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 12633,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, overexpression of EGFR C797S in addition to EGFR L747_P753delinsS and T790M conferred resistance to Tarceva (erlotinib) in transformed cells in culture (PMID: 29285266).",
            "molecularProfile": {
                "id": 28797,
                "profileName": "EGFR L747_P753delinsS EGFR T790M EGFR C797S"
            },
            "therapy": {
                "id": 4,
                "therapyName": "Erlotinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 10505,
                    "pubMedId": 29285266,
                    "title": "Characterization of the efficacies of osimertinib and nazartinib against cells expressing clinically relevant epidermal growth factor receptor mutations.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29285266"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 12640,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, overexpression of EGFR C797S in addition to other EGFR activating mutations including L858R, T790M, and exon 19 deletion (L747_P753delinsS) conferred resistance to Tarceva (erlotinib) in transformed cells in culture (PMID: 29285266).",
            "molecularProfile": {
                "id": 28798,
                "profileName": "EGFR C797S EGFR act mut"
            },
            "therapy": {
                "id": 4,
                "therapyName": "Erlotinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 10505,
                    "pubMedId": 29285266,
                    "title": "Characterization of the efficacies of osimertinib and nazartinib against cells expressing clinically relevant epidermal growth factor receptor mutations.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29285266"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 12638,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, overexpression of EGFR C797S in addition to other EGFR activating mutations including L858R, T790M, and exon 19 deletion (L747_P753delinsS) conferred resistance to Tagrisso (osimertinib) in transformed cells in culture (PMID: 29285266).",
            "molecularProfile": {
                "id": 28798,
                "profileName": "EGFR C797S EGFR act mut"
            },
            "therapy": {
                "id": 660,
                "therapyName": "Osimertinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 10505,
                    "pubMedId": 29285266,
                    "title": "Characterization of the efficacies of osimertinib and nazartinib against cells expressing clinically relevant epidermal growth factor receptor mutations.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29285266"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 12637,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, overexpression of EGFR C797S in addition to other EGFR activating mutations including L858R, T790M, and exon 19 deletion (L747_P753delinsS) conferred resistance to Nazartinib (EGF816) in transformed cells in culture (PMID: 29285266).",
            "molecularProfile": {
                "id": 28798,
                "profileName": "EGFR C797S EGFR act mut"
            },
            "therapy": {
                "id": 1309,
                "therapyName": "Nazartinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 10505,
                    "pubMedId": 29285266,
                    "title": "Characterization of the efficacies of osimertinib and nazartinib against cells expressing clinically relevant epidermal growth factor receptor mutations.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29285266"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 12639,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, overexpression of EGFR C797S in addition to other EGFR activating mutations including L858R, T790M, and exon 19 deletion (L747_P753delinsS) conferred resistance to Gilotrif (afatinib) in transformed cells in culture (PMID: 29285266).",
            "molecularProfile": {
                "id": 28798,
                "profileName": "EGFR C797S EGFR act mut"
            },
            "therapy": {
                "id": 623,
                "therapyName": "Afatinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 10505,
                    "pubMedId": 29285266,
                    "title": "Characterization of the efficacies of osimertinib and nazartinib against cells expressing clinically relevant epidermal growth factor receptor mutations.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29285266"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 12679,
            "approvalStatus": "Phase I",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I trial, three non-small cell lung carcinoma patients initially harboring EGFR T790M and/or an EGFR activating mutation demonstrated a partial response to ASP8273 treatment, but later progressed, demonstrating in cell-free DNA, a reemergence of EGFR T790M and/or the EGFR activating mutation and EGFR C797S (PMID: 28954786; NCT02113813).",
            "molecularProfile": {
                "id": 28798,
                "profileName": "EGFR C797S EGFR act mut"
            },
            "therapy": {
                "id": 1082,
                "therapyName": "Naquotinib",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 10584,
                    "pubMedId": 28954786,
                    "title": "A Phase I, Dose Escalation Study of Oral ASP8273 in Patients with Non-small Cell Lung Cancers with Epidermal Growth Factor Receptor Mutations.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28954786"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 12680,
            "approvalStatus": "Phase I",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I trial, three non-small cell lung carcinoma patients initially harboring EGFR T790M and/or an EGFR activating mutation demonstrated a partial response to ASP8273 treatment, but later progressed, demonstrating in cell-free DNA, a reemergence of EGFR T790M and/or the EGFR activating mutation and EGFR C797S (PMID: 28954786; NCT02113813).",
            "molecularProfile": {
                "id": 28833,
                "profileName": "EGFR T790M EGFR C797S EGFR act mut"
            },
            "therapy": {
                "id": 1082,
                "therapyName": "Naquotinib",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 10584,
                    "pubMedId": 28954786,
                    "title": "A Phase I, Dose Escalation Study of Oral ASP8273 in Patients with Non-small Cell Lung Cancers with Epidermal Growth Factor Receptor Mutations.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28954786"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 14303,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, transformed cells co-expressing EGFR C797S, EGFR exon19 del, and EGFR T854A were sensitive to treatment with Alunbrig (brigatinib) in culture, demonstrating reduced cell growth (PMID: 29702287).",
            "molecularProfile": {
                "id": 29956,
                "profileName": "EGFR exon 19 del EGFR C797S EGFR T854A"
            },
            "therapy": {
                "id": 634,
                "therapyName": "Brigatinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 11550,
                    "pubMedId": 29702287,
                    "title": "Identification of Mutation Accumulation as Resistance Mechanism Emerging in First-Line Osimertinib Treatment.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29702287"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 14226,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, transformed cells co-expressing EGFR C797S, EGFR exon 19 del, and EGFR T854A demonstrated a decreased response to Iressa (gefitinib) in culture when compared to Alunbrig (brigatinib) (PMID: 29702287).",
            "molecularProfile": {
                "id": 29956,
                "profileName": "EGFR exon 19 del EGFR C797S EGFR T854A"
            },
            "therapy": {
                "id": 751,
                "therapyName": "Gefitinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "decreased response",
            "references": [
                {
                    "id": 11550,
                    "pubMedId": 29702287,
                    "title": "Identification of Mutation Accumulation as Resistance Mechanism Emerging in First-Line Osimertinib Treatment.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29702287"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 14227,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, transformed cells co-expressing EGFR C797S, EGFR exon 19 del, and EGFR T854A demonstrated a decreased response to Gilotrif (afatinib) in culture when compared to Alunbrig (brigatinib) (PMID: 29702287).",
            "molecularProfile": {
                "id": 29956,
                "profileName": "EGFR exon 19 del EGFR C797S EGFR T854A"
            },
            "therapy": {
                "id": 623,
                "therapyName": "Afatinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "decreased response",
            "references": [
                {
                    "id": 11550,
                    "pubMedId": 29702287,
                    "title": "Identification of Mutation Accumulation as Resistance Mechanism Emerging in First-Line Osimertinib Treatment.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29702287"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 14228,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, transformed cells co-expressing EGFR C797S, EGFR exon 19 del, and EGFR T854A were resistant to treatment with Tagrisso (osimertinib) (PMID: 29702287).",
            "molecularProfile": {
                "id": 29956,
                "profileName": "EGFR exon 19 del EGFR C797S EGFR T854A"
            },
            "therapy": {
                "id": 660,
                "therapyName": "Osimertinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 11550,
                    "pubMedId": 29702287,
                    "title": "Identification of Mutation Accumulation as Resistance Mechanism Emerging in First-Line Osimertinib Treatment.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29702287"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 14229,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, transformed cells co-expressing EGFR C797S, EGFR L792H, and EGFR L858R were resistant to treatment with Gilotrif (afatinib) in culture (PMID: 29702287).",
            "molecularProfile": {
                "id": 29958,
                "profileName": "EGFR L792H EGFR C797S EGFR L858R"
            },
            "therapy": {
                "id": 623,
                "therapyName": "Afatinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 11550,
                    "pubMedId": 29702287,
                    "title": "Identification of Mutation Accumulation as Resistance Mechanism Emerging in First-Line Osimertinib Treatment.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29702287"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 14230,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, transformed cells co-expressing EGFR C797S, EGFR L792H, and EGFR L858R were resistant to treatment with Tagrisso (osimertinib) in culture (PMID: 29702287).",
            "molecularProfile": {
                "id": 29958,
                "profileName": "EGFR L792H EGFR C797S EGFR L858R"
            },
            "therapy": {
                "id": 660,
                "therapyName": "Osimertinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 11550,
                    "pubMedId": 29702287,
                    "title": "Identification of Mutation Accumulation as Resistance Mechanism Emerging in First-Line Osimertinib Treatment.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29702287"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 14296,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, transformed cells co-expressing EGFR C797S, EGFR L792H, and EGFR L858R demonstrated some efficacy to treatment with Iressa (gefitinib) in culture (PMID: 29702287).",
            "molecularProfile": {
                "id": 29958,
                "profileName": "EGFR L792H EGFR C797S EGFR L858R"
            },
            "therapy": {
                "id": 751,
                "therapyName": "Gefitinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 11550,
                    "pubMedId": 29702287,
                    "title": "Identification of Mutation Accumulation as Resistance Mechanism Emerging in First-Line Osimertinib Treatment.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29702287"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 14231,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, transformed cells co-expressing EGFR C797S, EGFR L792H, and EGFR L858R were resistant to treatment with Alunbrig (brigatinib) in culture (PMID: 29702287).",
            "molecularProfile": {
                "id": 29958,
                "profileName": "EGFR L792H EGFR C797S EGFR L858R"
            },
            "therapy": {
                "id": 634,
                "therapyName": "Brigatinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 11550,
                    "pubMedId": 29702287,
                    "title": "Identification of Mutation Accumulation as Resistance Mechanism Emerging in First-Line Osimertinib Treatment.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29702287"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 14301,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, transformed cells co-expressing EGFR C797S, EGFR L858R, and EGFR T854A demonstrated some resistance to Gilotrif (afatinib) in culture (PMID: 29702287).",
            "molecularProfile": {
                "id": 29959,
                "profileName": "EGFR C797S EGFR T854A EGFR L858R"
            },
            "therapy": {
                "id": 623,
                "therapyName": "Afatinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "predicted - resistant",
            "references": [
                {
                    "id": 11550,
                    "pubMedId": 29702287,
                    "title": "Identification of Mutation Accumulation as Resistance Mechanism Emerging in First-Line Osimertinib Treatment.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29702287"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 14300,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, transformed cells co-expressing EGFR C797S, EGFR L858R, and EGFR T854A demonstrated some resistance to Alunbrig (brigatinib) in culture (PMID: 29702287).",
            "molecularProfile": {
                "id": 29959,
                "profileName": "EGFR C797S EGFR T854A EGFR L858R"
            },
            "therapy": {
                "id": 634,
                "therapyName": "Brigatinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "predicted - resistant",
            "references": [
                {
                    "id": 11550,
                    "pubMedId": 29702287,
                    "title": "Identification of Mutation Accumulation as Resistance Mechanism Emerging in First-Line Osimertinib Treatment.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29702287"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 14297,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, transformed cells co-expressing EGFR C797S, EGFR L858R, and EGFR T854A demonstrated resistance to treatment with Tagrisso (osimertinib) (PMID: 29702287).",
            "molecularProfile": {
                "id": 29959,
                "profileName": "EGFR C797S EGFR T854A EGFR L858R"
            },
            "therapy": {
                "id": 660,
                "therapyName": "Osimertinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 11550,
                    "pubMedId": 29702287,
                    "title": "Identification of Mutation Accumulation as Resistance Mechanism Emerging in First-Line Osimertinib Treatment.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29702287"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 14298,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, transformed cells co-expressing EGFR C797S, EGFR L858R, and EGFR T854A demonstrated some resistance to Iressa (gefitinib) in culture (PMID: 29702287).",
            "molecularProfile": {
                "id": 29959,
                "profileName": "EGFR C797S EGFR T854A EGFR L858R"
            },
            "therapy": {
                "id": 751,
                "therapyName": "Gefitinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "predicted - resistant",
            "references": [
                {
                    "id": 11550,
                    "pubMedId": 29702287,
                    "title": "Identification of Mutation Accumulation as Resistance Mechanism Emerging in First-Line Osimertinib Treatment.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29702287"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 14491,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, transformed cells co-expressing EGFR C797S, EGFR P772_H773insGNP (referred to as D770_N771insNPG), and EGFR T790M did not respond to treatment with OBX1-012 in culture (PMID: 29754184).",
            "molecularProfile": {
                "id": 30023,
                "profileName": "EGFR P772_H773insGNP EGFR T790M EGFR C797S"
            },
            "therapy": {
                "id": 7094,
                "therapyName": "OBX1-012",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "predicted - resistant",
            "references": [
                {
                    "id": 11644,
                    "pubMedId": 29754184,
                    "title": "Discovery of a Potent and Mutant-Selective EGFR Inhibitor that Overcomes T790M-Mediated Resistance in Lung Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29754184"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 20731,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a retrospective analysis, EGFR C797S in cis with EGFR T790M were identified in 17 of 100 patients with non-small cell lung cancer at treatment discontinuation of Tagrisso (osimertinib) (PMID: 31839416).",
            "molecularProfile": {
                "id": 30025,
                "profileName": "EGFR T790M EGFR C797S"
            },
            "therapy": {
                "id": 660,
                "therapyName": "Osimertinib",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "predicted - resistant",
            "references": [
                {
                    "id": 18023,
                    "pubMedId": 31839416,
                    "title": "Next-generation sequencing based mutation profiling reveals heterogeneity of clinical response and resistance to osimertinib.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31839416"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 18387,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, transformed cells expressing EGFR C797S and EGFR T790M in cis were resistant to Gilotrif (afatinib) in culture (PMID: 29141884).",
            "molecularProfile": {
                "id": 30025,
                "profileName": "EGFR T790M EGFR C797S"
            },
            "therapy": {
                "id": 623,
                "therapyName": "Afatinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 10358,
                    "pubMedId": 29141884,
                    "title": "A method of high-throughput functional evaluation of EGFR gene variants of unknown significance in cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29141884"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 18389,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, transformed cells expressing EGFR C797S and EGFR T790M in cis were resistant to Erbitux (cetuximab) in culture (PMID: 29141884).",
            "molecularProfile": {
                "id": 30025,
                "profileName": "EGFR T790M EGFR C797S"
            },
            "therapy": {
                "id": 694,
                "therapyName": "Cetuximab",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 10358,
                    "pubMedId": 29141884,
                    "title": "A method of high-throughput functional evaluation of EGFR gene variants of unknown significance in cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29141884"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 18388,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, transformed cells expressing EGFR C797S and EGFR T790M in cis were resistant to Tagrisso (osimertinib) in culture (PMID: 29141884).",
            "molecularProfile": {
                "id": 30025,
                "profileName": "EGFR T790M EGFR C797S"
            },
            "therapy": {
                "id": 660,
                "therapyName": "Osimertinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 10358,
                    "pubMedId": 29141884,
                    "title": "A method of high-throughput functional evaluation of EGFR gene variants of unknown significance in cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29141884"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 14493,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, transformed cells co-expressing EGFR C797S and EGFR T790M were sensitive to treatment with OBX1-012 in culture, demonstrating decreased cell viability (PMID: 29754184).",
            "molecularProfile": {
                "id": 30025,
                "profileName": "EGFR T790M EGFR C797S"
            },
            "therapy": {
                "id": 7094,
                "therapyName": "OBX1-012",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 11644,
                    "pubMedId": 29754184,
                    "title": "Discovery of a Potent and Mutant-Selective EGFR Inhibitor that Overcomes T790M-Mediated Resistance in Lung Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29754184"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 18386,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, transformed cells expressing EGFR C797S and EGFR T790M in cis were resistant to Tarceva (erlotinib) in culture (PMID: 29141884).",
            "molecularProfile": {
                "id": 30025,
                "profileName": "EGFR T790M EGFR C797S"
            },
            "therapy": {
                "id": 4,
                "therapyName": "Erlotinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 10358,
                    "pubMedId": 29141884,
                    "title": "A method of high-throughput functional evaluation of EGFR gene variants of unknown significance in cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29141884"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 18385,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, transformed cells expressing EGFR C797S and EGFR T790M in cis were resistant to Iressa (gefitinib) in culture (PMID: 29141884).",
            "molecularProfile": {
                "id": 30025,
                "profileName": "EGFR T790M EGFR C797S"
            },
            "therapy": {
                "id": 751,
                "therapyName": "Gefitinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 10358,
                    "pubMedId": 29141884,
                    "title": "A method of high-throughput functional evaluation of EGFR gene variants of unknown significance in cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29141884"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 18044,
            "approvalStatus": "Phase I",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I trial, tertiary EGFR mutations including C797S (n=3) and L718V (n=1) were identified as a potential acquired resistance mechanism in 13% (4/30) of patients with non-small cell lung cancer harboring EGFR T790M whose disease progressed while on Abivertinib (AC0010) treatment (PMID: 31027916; NCT02330367).",
            "molecularProfile": {
                "id": 30025,
                "profileName": "EGFR T790M EGFR C797S"
            },
            "therapy": {
                "id": 2909,
                "therapyName": "Abivertinib",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "predicted - resistant",
            "references": [
                {
                    "id": 15973,
                    "pubMedId": 31027916,
                    "title": "Analysis of resistance mechanisms to abivertinib, a third-generation EGFR tyrosine kinase inhibitor, in patients with EGFR T790M-positive non-small cell lung cancer from a phase I trial.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31027916"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 15134,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical study, a patient with non-small cell lung cancer initially responded to Tagrisso (osimertinib), and EGFR C797G, C797S, L858R, L781Q, T790M, and TFG-ALK were identified in post-progression tumor samples (PMID: 29883838).",
            "molecularProfile": {
                "id": 30781,
                "profileName": "TFG - ALK EGFR L718Q EGFR T790M EGFR C797G EGFR C797S EGFR L858R"
            },
            "therapy": {
                "id": 660,
                "therapyName": "Osimertinib",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "predicted - resistant",
            "references": [
                {
                    "id": 12672,
                    "pubMedId": 29883838,
                    "title": "Receptor Tyrosine Kinase Fusions and BRAF Kinase Fusions are Rare but Actionable Resistance Mechanisms to EGFR Tyrosine Kinase Inhibitors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29883838"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 18293,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical case study, a patient with non-small cell lung cancer harboring EGFR E746_T751delinsV developed resistance after 10 months of treatment, demonstrating systemic progression, and via cell-free DNA testing, was subsequently found to have acquired EGFR C797S (PMID: 31377341).",
            "molecularProfile": {
                "id": 33123,
                "profileName": "EGFR E746_T751delinsV EGFR C797S"
            },
            "therapy": {
                "id": 660,
                "therapyName": "Osimertinib",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "predicted - resistant",
            "references": [
                {
                    "id": 16121,
                    "pubMedId": 31377341,
                    "title": "EGFR-Mutated Lung Cancers Resistant to Osimertinib through EGFR C797S Respond to First-Generation Reversible EGFR Inhibitors but Eventually Acquire EGFR T790M/C797S in Preclinical Models and Clinical Samples.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31377341"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 18294,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical case study, a patient with non-small cell lung cancer co-harboring EGFR C797S and EGFR E746_T751delinsV treated with Tarceva (erlotinib) demonstrated disease control for four months, but at five months developed progression, and cell-free DNA testing one month before progression revealed acquisition of EGFR T790M (PMID: 31377341).",
            "molecularProfile": {
                "id": 33128,
                "profileName": "EGFR E746_T751delinsV EGFR T790M EGFR C797S"
            },
            "therapy": {
                "id": 4,
                "therapyName": "Erlotinib",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "predicted - resistant",
            "references": [
                {
                    "id": 16121,
                    "pubMedId": 31377341,
                    "title": "EGFR-Mutated Lung Cancers Resistant to Osimertinib through EGFR C797S Respond to First-Generation Reversible EGFR Inhibitors but Eventually Acquire EGFR T790M/C797S in Preclinical Models and Clinical Samples.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31377341"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 21245,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, EGFR C797S was identified in 24% (12/50) of Vizimpro (dacomitinib)-resistant clones generated through ENU mutagenesis in transformed cells expressing EGFR G719A in culture (PMID: 29410323).",
            "molecularProfile": {
                "id": 35882,
                "profileName": "EGFR G719A EGFR C797S"
            },
            "therapy": {
                "id": 714,
                "therapyName": "Dacomitinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "predicted - resistant",
            "references": [
                {
                    "id": 11558,
                    "pubMedId": 29410323,
                    "title": "EGFR T790M and C797S Mutations as Mechanisms of Acquired Resistance to Dacomitinib.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29410323"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        }
    ],
    "molecularProfiles": [
        {
            "id": 11686,
            "profileName": "EGFR C797S",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 11688,
            "profileName": "EGFR E746_A750del EGFR T790M EGFR C797S",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 11691,
            "profileName": "EGFR E746_A750del EGFR C797S",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 11696,
            "profileName": "EGFR C797S EGFR L858R",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 14858,
            "profileName": "EGFR exon 19 del EGFR T790M EGFR C797S",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 14859,
            "profileName": "EGFR T790M EGFR C797S EGFR L858R",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 21570,
            "profileName": "EGFR exon 19 del EGFR C797S",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 27534,
            "profileName": "EGFR D770delinsGY EGFR C797S",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 28797,
            "profileName": "EGFR L747_P753delinsS EGFR T790M EGFR C797S",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 28798,
            "profileName": "EGFR C797S EGFR act mut",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 28833,
            "profileName": "EGFR T790M EGFR C797S EGFR act mut",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 29956,
            "profileName": "EGFR exon 19 del EGFR C797S EGFR T854A",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 29958,
            "profileName": "EGFR L792H EGFR C797S EGFR L858R",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 29959,
            "profileName": "EGFR C797S EGFR T854A EGFR L858R",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 30023,
            "profileName": "EGFR P772_H773insGNP EGFR T790M EGFR C797S",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 30025,
            "profileName": "EGFR T790M EGFR C797S",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 30781,
            "profileName": "TFG - ALK EGFR L718Q EGFR T790M EGFR C797G EGFR C797S EGFR L858R",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 33123,
            "profileName": "EGFR E746_T751delinsV EGFR C797S",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 33128,
            "profileName": "EGFR E746_T751delinsV EGFR T790M EGFR C797S",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 35882,
            "profileName": "EGFR G719A EGFR C797S",
            "profileTreatmentApproaches": [
                
            ]
        }
    ],
    "allTranscriptCoordinates": [
        {
            "id": 135545,
            "transcript": "NM_005228",
            "gDna": "chr7:g.55181398T>A",
            "cDna": "c.2389T>A",
            "protein": "p.C797S",
            "sourceDb": "RefSeq",
            "refGenomeBuild": "GRCh38/hg38"
        }
    ]
}